TAK Oct 2023 20.000 put
| Previous close | 3.7500 |
| Open | 3.7500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 20.00 |
| Expiry date | 2023-10-20 |
| Day's range | 3.7500 - 3.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Business WireTakeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress
CAMBRIDGE, Mass. & OSAKA, Japan, May 26, 2023--Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its expanding oncology pipeline and established product portfolio at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 2-6, 2023, in Chicago, Ill. and the 31st Congress of the European Hematology Association (EHA), June 8-11, 2023, in Frankfurt, Germany.
Business WireTakeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
OSAKA, Japan & CAMBRIDGE, Mass. & HONG KONG & SHANGHAI & FLORHAM PARK, N.J., May 25, 2023--Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (HUTCHMED) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of the New Drug Application (NDA) for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated m
ZacksReasons to Add Puma (PBYI) Stock to Your Portfolio Right Now
Puma Biotechnology (PBYI), a top-ranked stock, has a promising development candidate, alisertib. Its only marketed product, Nerlynx (neratinib), is witnessing improving demand trends in the United States.
Business WireU.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
OSAKA, Japan & CAMBRIDGE, Mass., May 17, 2023--Takeda (TSE: 4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Takeda’s Biologics License Application (BLA) for TAK-755, an enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP), an ADAMTS13 deficiency disorder. The TAK-755 application was accepted by the FDA on May 16th, and has been granted Priority Review.
Business WireTakeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook
OSAKA, Japan & CAMBRIDGE, Mass., May 11, 2023--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for fiscal year 2022 (period ended March 31, 2023), delivering or exceeding management guidance, driven by the performance of its Growth & Launch Products.
CNW GroupTakeda Presents Real-World Clinical Effectiveness and Safety Results of Vedolizumab (ENTYVIO®) and Ustekinumab as First-Line Biologic Treatment for Crohn's Disease
Takeda Canada Inc. ("Takeda") announces results from the EVOLVE Expansion study, which evaluated the safety and efficacy of vedolizumab (ENTYVIO®), a gut-selective α4β7-integrin inhibitor and ustekinumab (UST), an IL-12/23 p40 inhibitor, as first-line biologic treatment for patients with Crohn's disease (CD). The data were presented as an oral presentation at Digestive Disease Week® (DDW) 2023 in Chicago, IL.1
Business WireTakeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
OSAKA, Japan & CAMBRIDGE, Mass., April 27, 2023--Takeda (TSE:4502/NYSE:TAK) ("Takeda") today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) resubmission for the investigational subcutaneous (SC) administration of Entyvio® (vedolizumab) for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) after induction therapy with Entyvio intravenous. The resubmission is intended to address FDA f
CNW GroupTakeda has Secured Three-Year Contract in Key Immunoglobulin Category
Takeda Canada Inc. (Takeda) has entered into a three-year agreement with Canadian Blood Services (CBS) that includes GAMMAGARD LIQUID®, GAMMAGARD® S/D and CUVITRU®, resulting from CBS's request for proposal for immunoglobulin therapy within its formulary mix. The three-year agreement is the second consecutive time Takeda has received a significant award for these products with the option for two one-year extensions, reinforcing the company's leadership position in immunoglobulin therapy.
Business WireTakeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children
CAMBRIDGE, Mass., April 11, 2023--U.S. FDA approval of the expanded indication for the use of HYQVIA in the treatment of children 2-16 years old with primary immunodeficiency.
Business WireTakeda Announces New U.S. Corporate Social Responsibility (CSR) Program Partners
CAMBRIDGE, Mass., April 03, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that 21 new U.S. non-profit organizations have received grants as part of the company’s $19.5 million commitment to its FY2022 Corporate Social Responsibility program. Combined with its initial investment of $20 million in FY2021, Takeda is delivering a collective amount of $39.5 million to help improve equity among under-resourced communities in the areas of health, education, the environment and providing access to he
ZacksShould Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Business WireTakeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine
OSAKA, Japan & CAMBRIDGE, Mass., March 30, 2023--Takeda (TSE:4502/NYSE:TAK) today confirmed that the New England Journal of Medicine (NEJM) has published positive data from the Phase 4 EARNEST study of vedolizumab for the treatment of chronic pouchitis. The NEJM article is titled "Vedolizumab for the Treatment of Chronic Pouchitis".
Business WireTakeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
OSAKA, Japan, March 30, 2023--Takeda (TSE:4502/NYSE:TAK) announced that its Board of Directors today decided that it will propose a new candidate for independent external director at the 147th Ordinary Meeting of Shareholders on June 28th, 2023. The new candidate, Miki Tsusaka, will join the board effective June 28th, if approved by the shareholders. Furthermore, Masato Iwasaki, Representative Director, Japan General Affairs expressed his intention to retire on the same day. All other current bo
Business WireBioLife Plasma Services Opens its 200th Plasma Donation Center in the U.S.
BANNOCKBURN, Ill., March 27, 2023--BioLife Plasma Services, part of the global biopharmaceutical company Takeda, today announced the opening of its 200th plasma donation center in the United States (U.S.)., with new locations in West Springfield, Mass. and Pearland, Texas. This is an important milestone in BioLife’s broader expansion plans to continue opening centers in the U.S. to address the urgent and growing need for plasma.
Business WireTakeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis
OSAKA, Japan & CAMBRIDGE, Mass., March 18, 2023--Takeda (TSE:4502/NYSE:TAK) today announced positive results from a Phase 2b clinical trial of TAK-279 (NDI-034858), a highly selective, oral allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis. The study met its primary and secondary endpoints, with a statistically significant greater proportion of TAK-279 patients achieving Psoriasis Area and Severity Index (PASI) 75, 90 and 100 in the 5mg, 15mg and
ZacksAre Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Motley Fool2 Incredibly Cheap High-Yield Dividend Stocks to Buy Now
High-yield dividend stocks can be a great way to protect your portfolio from market volatility. Read on to find out more about these two high-yield dividend stocks. Ford, and most of its contemporaries, took a big step backward last year over concerns about the impact of rising interest rates on demand for new vehicles.
ZacksIs Grifols (GRFS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Business WireTakeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
OSAKA, Japan & CAMBRIDGE, Mass., February 18, 2023--Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo.1 Intestinal aGvHD is a serious complication characterized by inflammation
Motley FoolIs This the Telltale Sign to Sell Novavax Stock?
Unfortunately, Novavax (NASDAQ: NVAX) hasn't had great timing. The company was late to the party in winning authorizations for its COVID-19 vaccine, Nuvaxovid. If you only looked at Novavax's press releases, you wouldn't know about some recent bad news for the company.
Business WireTakeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
OSAKA, Japan & CAMBRIDGE, Mass., February 08, 2023--Takeda today announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. from Nimbus Therapeutics, LLC
Business WireU.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
OSAKA, Japan & CAMBRIDGE, Mass., February 03, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of TAKHZYRO® (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients 2 to <12 years of age.1 Prior to today’s approval, the only approved routine prophylaxis treatment options for children 6 to <12 years of age requir
ReutersJapan's Takeda's profit slips 13%, pipeline bolsters outlook
Japan's Takeda Pharmaceutical Co posted a 13% drop in operating earnings for the nine months ended December but kept its profit outlook for the fiscal year unchanged as it works to bolster its drugs pipeline. Takeda's annual operating profit forecast of 530 billion yen already lags a Refinitiv analysts' consensus forecast of 593.9 billion yen. European Union regulators in December approved Takeda's vaccine for dengue fever, branded as QDENGA.
Business WireTakeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3
OSAKA, Japan, February 02, 2023--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the third quarter of fiscal year 2022 (period ended December 31, 2022).
Business WireTakeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
OSAKA, Japan & CAMBRIDGE, Mass., January 23, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with HUTCHMED (China) Limited (Nasdaq/AIM: HCM, HKEX: 13) and its subsidiary HUTCHMED Limited, for the further development and commercialization of fruquintinib outside of mainland China, Hong Kong and Macau.